Analysts Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Price Target at $26.63

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have received a consensus recommendation of “Buy” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. Ten research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $26.63.

A number of analysts have weighed in on EYPT shares. Citigroup began coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $33.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. Robert W. Baird dropped their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. Chardan Capital restated a “buy” rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, February 6th. Finally, Scotiabank assumed coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price objective for the company.

EyePoint Pharmaceuticals Stock Up 1.1 %

Shares of EyePoint Pharmaceuticals stock opened at $6.35 on Thursday. The firm’s 50 day moving average is $7.74 and its 200 day moving average is $8.73. EyePoint Pharmaceuticals has a 1 year low of $5.90 and a 1 year high of $30.78.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in EyePoint Pharmaceuticals by 28.3% during the fourth quarter. Geode Capital Management LLC now owns 1,538,902 shares of the company’s stock worth $11,467,000 after buying an additional 339,846 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of EyePoint Pharmaceuticals by 3.1% in the 4th quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company’s stock valued at $30,825,000 after purchasing an additional 125,519 shares during the period. Wellington Management Group LLP lifted its stake in shares of EyePoint Pharmaceuticals by 3.2% in the 4th quarter. Wellington Management Group LLP now owns 177,316 shares of the company’s stock valued at $1,321,000 after purchasing an additional 5,552 shares during the period. Schroder Investment Management Group boosted its position in shares of EyePoint Pharmaceuticals by 118.1% during the 4th quarter. Schroder Investment Management Group now owns 270,336 shares of the company’s stock valued at $1,898,000 after purchasing an additional 146,403 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in EyePoint Pharmaceuticals by 6.4% during the fourth quarter. JPMorgan Chase & Co. now owns 395,444 shares of the company’s stock worth $2,946,000 after purchasing an additional 23,686 shares during the period. 99.41% of the stock is owned by institutional investors.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.